Newswire (Published: Monday, June 5, 2017, Received: Thursday, June 1, 2017, 11:03:47 PM CDT)
Word Count: 482
Research Conducted at University of Colorado Has Provided New Information about Prostate Cancer (Abiraterone acetate and prednisone in chemotherapy-na?ve prostate cancer patients: rationale, evidence and clinical utility)
By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Oncology - Prostate Cancer have been presented. According to news reporting originating in Aurora, Colorado, by NewsRx journalists, research stated, "Abiraterone acetate 1000 mg/day, combined with prednisone 5 mg PO twice daily, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate is the oral prodrug of abiraterone, a specific CYP17 inhibitor that blocks androgen biosynthesis within the adrenal glands, testes and tumor microenvironment."
Financial support for this research came from Janssen Scientific Affairs, LLC (see also Oncology - Prostate Cancer).
The news reporters obtained a quote from the research from the University of Colorado, "In a phase III trial of men with asymptomatic or minimally symptomatic, chemotherapy-na?ve mCRPC, treatment with oral abiraterone acetate plus prednisone led to a statistically significant improvement in the co-primary endpoints of overall survival and radiographic progression-free survival when compared with placebo plus prednisone. In long-term follow-up of phase III trials, the incidence of corticosteroid-associated adverse events was 25.5% in the abiraterone acetate plus prednisone arm compared with 23.3% in the placebo plus prednisone arm. The need for regular patient monitoring and appropriate management of symptoms during long-term use of prednisone must be placed in context with the improvement in survival seen with abiraterone plus prednisone. Within the multidisciplinary environment that is emerging to meet quality and cost imperatives, abiraterone acetate plus prednisone is suitable for use in the chemotherapy-na?ve population with minimal symptoms as well as in patients who have been treated with docetaxel and may have symptomatic disease."
According to the news reporters, the research concluded: "Ongoing trials are evaluating the role of abiraterone acetate plus prednisone in patients with nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer, while further trials in the mCRPC setting are evaluating its use in combination regimens."
For more information on this research see: Abiraterone acetate and prednisone in chemotherapy-na?ve prostate cancer patients: rationale, evidence and clinical utility. Therapeutic Advances In Medical Oncology, 2017;9(5):319-333. (Sage Publications - www.sagepub.com/; Therapeutic Advances In Medical Oncology - tam.sagepub.com)
Our news correspondents report that additional information may be obtained by contacting E.D. Crawford, Professor of Surgery, Urology, Radiation Oncology, Head Urologic Oncology, University of Colorado, Denver, Mail Stop #F 710, PO Box #6510, Aurora, CO 80045, United States. Additional authors for this research include N.D. Shore, D.P. Petrylak, C.S. Higano and C.J Ryan.
Keywords for this news article include: Aurora, Colorado, Oncology, Chemotherapy, United States, Article Review, Prostate Cancer, Drugs and Therapies, Prostatic Neoplasms, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
University of Colorado Denver
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Medical and Pharmaceutical Regulation
Drug and Device Approval Process
Treatments and Therapies